You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Definition

Epidemiology

Clinical

Laboratory

Proven History of trauma or contact with a cat with sporotrichosis Lesions compatible with sporotrichosis Positive culture and/or histopathology (microbiological evidence)
Probable History of trauma or contact with a cat with sporotrichosis Lesions compatible with sporotrichosis Human: Negative culture and/or histopathology.†
Possible History of trauma or contact with a cat with sporotrichosis Lesions compatible with sporotrichosis Absent
Non-CTS History of trauma or contact with a cat with sporotrichosis Lesions compatible with sporotrichosis Negative culture and/or histopathology for Sporothrix spp.†

Table 1. Cat-transmitted sporotrichosis case definitions used in study of human cases in Curitiba, Brazil, 2011–2022*

*Adapted from Guide to Health Surveillance, 5th ed[23–25]. CTS, cat-transmitted sporotrichosis. †Negative culture for Sporothrix spp. alone does not rule out diagnosis (limitation of the culture).

Table 2.  

Characteristic

No. (%) patients

Sex  
   F 140 (65)
   M 76 (35)
Age range, y  
   ≤10 17 (8)
   11–17 12 (6)
   18–30 45 (21)
   31–60 109 (50)
   >60 33 (15)
Occupation  
   Unemployed 42 (19)
   Student 42 (19)
   Retired 23 (11)
   Domestic worker 17 (8)
   Veterinarian or veterinary student 17 (8)
   Administrator 11 (5)
   Teacher 3 (1)
   Pet sitter 3 (1)
   Gardener 2 (1)
   Butcher 2 (1)
   Others 54 (26)

Table 2. Sociodemographic characteristics in study of human sporotrichosis cases in Curitiba, Brazil, 2011–2022

CME / ABIM MOC

Rising Incidence of Sporothrix brasiliensis Fungal Infections in Curitiba, Brazil, 2011-2022

  • Authors: Regielly C. R. Cognialli, MS; Diego H. Cáceres, MS; Fernanda de A. G. D. Bastos, MS; Francelise B. Cavassin, PhD; Bruno P. R. Lustosa, MS; Vânia A. Vicente, PhD; Giovanni L. Breda, MS; Izabella Santos-Weiss, PhD; Flávio Queiroz-Telles, PhD
  • CME / ABIM MOC Released: 6/16/2023
  • Valid for credit through: 6/16/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for infectious disease clinicians, dermatologists, ophthalmologists, public health officials, and other clinicians caring for patients with or at risk for cat-transmitted sporotrichosis caused by the emerging pathogen Sporothrix brasiliensis.

The goal of this activity is for learners to be better able to describe cat-transmitted sporotrichosis disease incidence, clinical syndromes, and geographic distribution, based on a medical record review of 216 sporotrichosis cases diagnosed during 2011 to 2022 in Hospital de Clínicas, a tertiary referral hospital in Curitiba, Brazil.

Upon completion of this activity, participants will:

  • Assess cat-transmitted sporotrichosis disease incidence, demographics, and clinical and laboratory findings, based on a medical record review of 216 sporotrichosis cases diagnosed during 2011 to 2022 in Curitiba, Brazil
  • Evaluate cat-transmitted sporotrichosis geographic distribution and incidence trends, based on a medical record review of 216 sporotrichosis cases diagnosed during 2011 to 2022 in Curitiba, Brazil
  • Determine the clinical and public health implications of cat-transmitted sporotrichosis disease incidence, clinical syndromes, and geographic distribution, based on a medical record review of 216 sporotrichosis cases diagnosed during 2011 to 2022 in Curitiba, Brazil


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Regielly C. R. Cognialli, MS

    Hospital de Clínicas
    Federal University of Paraná
    Curitiba, Brazil

    Postgraduate Program in Internal Medicine and Health Science
    Federal University of Paraná
    Curitiba, Brazil

  • Diego H. Cáceres, MS

    Immuno-Mycologics
    Norman, Oklahoma

    Center of Expertise in Mycology Radboudumc/CWZ
    Nijmegen, The Netherlands

    Studies in Translational Microbiology and Emerging Diseases Research Group
    School of Medicine and Health Sciences
    Universidad del Rosario
    Bogota, Colombia

  • Fernanda de A. G. D. Bastos, MS

    Postgraduate Program in Internal Medicine and Health Science
    Federal University of Paraná
    Curitiba, Brazil

  • Francelise B. Cavassin, PhD

    Faculty of Medical Sciences
    Faculdades Pequeno Príncipe
    Curitiba, PR, Brazil

  • Bruno P. R. Lustosa, MS

    Basic Pathology Department, Microbiology, Parasitology and Pathology and Bioprocess Engineering and Biotechnology Graduate Programs
    Federal University of Paraná
    Curitiba, Brazil

  • Vânia A. Vicente, PhD

    Basic Pathology Department, Microbiology, Parasitology and Pathology and Bioprocess Engineering and Biotechnology Graduate Programs
    Federal University of Paraná
    Curitiba, Brazil

  • Giovanni L. Breda, MS

    Hospital de Clínicas
    Federal University of Paraná
    Curitiba, Brazil

  • Izabella Santos-Weiss, PhD

    Department of Clinical Analysis
    Federal University of Paraná
    Curitiba, Brazil

  • Flávio Queiroz-Telles, PhD

    Department of Public Health
    Hospital de Clínicas
    Federal University of Paraná
    Curitiba, Brazil

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Laurie Barclay, MD, has no relevant financial relationships.

Editor

  • Tony Pearson-Clarke, MS

    Copyeditor
    Emerging Infectious Diseases

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Rising Incidence of Sporothrix brasiliensis Fungal Infections in Curitiba, Brazil, 2011-2022

Authors: Regielly C. R. Cognialli, MS; Diego H. Cáceres, MS; Fernanda de A. G. D. Bastos, MS; Francelise B. Cavassin, PhD; Bruno P. R. Lustosa, MS; Vânia A. Vicente, PhD; Giovanni L. Breda, MS; Izabella Santos-Weiss, PhD; Flávio Queiroz-Telles, PhDFaculty and Disclosures

CME / ABIM MOC Released: 6/16/2023

Valid for credit through: 6/16/2024, 11:59 PM EST

processing....

Abstract and Introduction

Abstract

Zoonotic outbreaks of sporotrichosis are increasing in Brazil. We examined and described the emergence of cat-transmitted sporotrichosis (CTS) caused by the fungal pathogen Sporothrix brasiliensis. We calculated incidence and mapped geographic distribution of cases in Curitiba, Brazil, by reviewing medical records from 216 sporotrichosis cases diagnosed during 2011–May 2022. Proven sporotrichosis was established in 84 (39%) patients and probable sporotrichosis in 132 (61%). Incidence increased from 0.3 cases/100,000 outpatient visit-years in 2011 to 21.4 cases/100,000 outpatient visit-years in 2021; of the 216 cases, 58% (n = 126) were diagnosed during 2019–2021. The main clinical form of sporotrichosis was lymphocutaneous (63%), followed by localized cutaneous (24%), ocular (10%), multisite infections (3%), and cutaneous disseminated (<0.5%). Since the first report of CTS in Curitiba in 2011, sporotrichosis has increased substantially, indicating continuous disease transmission. Clinician and public awareness of CTS and efforts to prevent transmission are needed.

Introduction

Sporotrichosis, the most prevalent implantation mycosis worldwide, is caused by fungi of genus Sporothrix[1–4]. In some regions of Brazil, sporotrichosis has been referred to as cat disease because of its zoonotic transmission from felines. Since 1990, a new Sporothrix species, S. brasiliensis, has emerged rapidly as an agent of cat-transmitted sporotrichosis (CTS)[5]. Initially identified primarily in Rio de Janeiro, highly virulent S. brasiliensis causes a notable level of epizootic disease involving cats, dogs, and humans[5–12] that is emerging and expanding geographically across Brazil[7–9,11] and is now a major public health problem[12]. Originally, CTS was reported primarily in the South and Southeast regions of Brazil, but by 2022, CTS was reported in 25 of its 26 states, as well as in neighboring Argentina, Chile, and Paraguay (Figure 1)[2,9,13–18]. In 2022, a case of cutaneous CTS caused by S. brasiliensis was reported in a veterinarian in the United Kingdom who was infected by an imported cat with sporotrichosis[19,20].

Rio de Janeiro state, in the Southeast region of Brazil, has the highest prevalence of CTS, >8,900 human cases reported since the beginning of the outbreak, followed by Rio Grande do Sul (South region) with 181 human cases[14,15,21]. In Paraná state, also in the South region, public health officials and clinicians have been alarmed by the emergence of CTS, but epidemiologic and clinical data on this disease in this jurisdiction are lacking because reporting is not mandatory[11,22]. Therefore, we performed a retrospective, descriptive study of human CTS to describe the characteristics of patients with sporotrichosis, based on a decade of experience in a single medical institution, the Hospital de Clínicas of the Federal University of Paraná (HC/UFPR), a tertiary referral hospital in Curitiba, Paraná’s largest city. Our study was approved by the HC/UFPR ethical committee (registration no. 12379819.4.0000.0096).